.png){kind=icon}
.png){kind=icon}
Return
The potential of CAR T cells in autoimmune diseases
.png){kind=icon}
PRE
AI
J
M
I
I
N
DOI：10.1080/1750743X.2025.2558348.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
CAR T cell therapy represents an emerging, promising approach in the field of autoimmune diseases. Unlike monoclonal antibodies, CAR T cells offer a deeper B cell depletion than monoclonal antibodies through their ability to infiltrate tissues and their independence from effector mechanisms. Early data from case reports and phase I/II studies demonstrate encouraging clinical responses in patients with severely refractory autoimmune disorders. CD19, BCMA and dual-targeting CAR constructs were generally well tolerated with limited safety concerns. This promising data encourages further research investigating CAR T cell therapy in a broader range of autoimmune indications and to advance CAR T constructs to improve efficacy, safety, and clinical application. In this review, we explore the rationale of using CAR T cell therapy in autoimmune diseases, summarize relevant clinical data, and highlight future perspectives within the field.
Keywords:
Chimeric antigen receptor T cell
CAR T cell therapy
autoimmune diseases
cell therapy
autoreactive B cells
Journal
J
IF:
2.9
Papers:
2.1K
Citations:
3.2K
Organization
Cited Papers